TipRanks measures analysts' "success rate" based on how their calls perform relative to the S&P 500 and the statistical difficulty of their calls.* Tetraphase ended 3Q14 with $56 million in cash and equivalents, but added $81 million in net proceeds from a public offering of common shares in October 2014. Tetraphase's current cash on hand should be sufficient to support its operations, including pre-commercialization activities for eravacycline, through at least 3Q16."